Associate Medical Director, CRC Center
Oncology
Dr. Cathy Eng, MD
|
|
Give Review
Doctor Cathy Eng, MD works in the field of Oncology. He attended Drexel University College of Medicine. He received 1 awards: "Regional Top Doctor". Dr. Cathy Eng is also published. He has 41 publications published. The lastest publication: "The Treatment of Colorectal Cancer During Pregnancy: Cytotoxic Chemotherapy and Targeted Therapy Challenges.' Cathy accepts Medicare payments and is registered with Medicare.gov.
Publications
- Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with ColoRectal Cancer.
- Transthoracic Port Placement Increases Safety of Total Laparoscopic Posterior Sectionectomy.
- Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal CAnal.
- Challenges of efficacy assessments in pseudomyxoma peritonea.
- Overtreatment of Young Adults With Colon Cancer: More Intense Treatments With Unmatched Survival Gains.
- Association between KRAS mutation and lung metastasis in advanced coloRectal cancer.
- The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the Anal ca...
- Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated ColoRectal Cancer.
- Quantitative Sensory Analysis of Peripheral Neuropathy Produced by Colorectal Cancer and its Exacerbation by Cumulative Dose of Oxaliplatin Chemotherapy.
- Definitive Chemoradiation for Squamous Cell Carcinoma of the Rectum.
- Preoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary coloRectal carcinoma.
- Optimal management of squamous cell carcinoma of the Anal cAnal: where are we now?
- Optimal Treatment Strategies for Anal Cancer.
- Clinicopathologic Characteristics and Gene Expression Analyses of Non-KRAS 12/13, RAS-Mutated Metastatic Colorectal Cancer.
- Cetuximab in Refractory Squamous Cell Carcinoma of the Anal CAnal.
- Definitive chemoradiation in oligometastatic squamous cell carcinoma of the Anal cAnal.
- Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007.
- Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial.
- Preoperative Radiation Therapy With Concurrent Capecitabine, Bevacizumab, and Erlotinib for Rectal Cancer: A Phase 1 Trial.
- Atypical Metastatic Presentations in ColoRectal Cancer: A Case Series.
- Selective roles of E2Fs for ErbB2- and Myc-mediated mammary tumorigenesis.
- Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with Rectal cancer who undergo resection after ...
- Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the Anal cAnal.
- Will PICCOLO affect metastatic coloRectal cancer therapy?
- Improving the AJCC/TNM staging for adenocarcinomas of the appendix: the prognostic impact of histological grade.
- Intensity-modulated Radiation Therapy With Concurrent Chemotherapy for Anal Cancer: Outcomes and Toxicity.
- Metformin use and improved response to therapy in Rectal cancer.
- The promise of mTOR inhibitors in the treatment of coloRectal cancer.
- Pathologic complete response in poorly differentiated adenocarcinomas of the appendix: A case series.
- Genetic Polymorphisms in MicroRNA-Related Genes as Predictors of Clinical Outcomes in ColoRectal Adenocarcinoma Patients.
- Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced coloRectal adenocarcinoma.
- Neoadjuvant Treatment Response As an Early Response Indicator for Patients With Rectal Cancer.
- Intensity-modulated radiation therapy for the treatment of squamous cell Anal cancer with para-aortic nodal involvement.
- Sacral insufficiency fractures after preoperative chemoradiation for Rectal cancer: incidence, risk factors, and clinical course.
- Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the Small bowel and ampulla of Vater.
- Toxic effects and their management: daily clinical challenges in the treatment of coloRectal cancer.
- Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic coloRectal metastases.
- Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in coloRectal cancer.
- The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic coloRectal cancer.
- The Treatment of ColoRectal Cancer During Pregnancy: Cytotoxic Chemotherapy and Targeted Therapy Challenges.
Schools
Hahnemann Univ Sch Of Med
Hahnemann University
Rush Presbyn St Luke39S Chicago
St Barnabas Med Center
University Chicago Med Center
Procedures Preformed
- Prostate Cancer Screening Exam (DRE)
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Blue Card PPO
- Blue Choice
- CHAMPVA
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- Coventry Health Care
- First Health (Coventry Health Care) PPO
- HealthSmart
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- Regional Top Doctor
Education
-
University of Chicago -
Rush University Medical Center -
St Barnabas Medical Center -
Drexel University - Hahnemann University Hospital -
Drexel University College of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1558469767 | |
| NPPES Provider LastName | ENG | |
| NPPES Provider FirstName | CATHY | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 176.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1558469767 |
| Last Name Of The Provider | ENG |
| First Name Of The Provider | CATHY |
| View All |
Similar Doctors
|
|
Dr. Fredrick B. Hagemeister, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Nizar M. Tannir, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Sumit K. Subudhi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eduardo D. Bruera, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Jaffer A. Ajani, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Mehmet A. Bilen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Werner A. Bleyer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pierre Saintigny, MD
This Doctor is OpenDoctor Recommended.
|